髋关节表面置换植入物市场（2026—2031）
髋关节表面置换植入物市场规模预计由2026年的8.8亿美元增至2031年的12.1亿美元，预测期复合年增长率为6.72%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
髋关节表面置换植入物市场规模预计由2026年的8.8亿美元增至2031年的12.1亿美元，预测期复合年增长率为6.72%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 6.72% | 机构预测 |
| 市场规模 | 2026 | USD 0.88 billion | 机构预测 |
| 市场规模 | 2031 | USD 1.21 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| end_user | hospitals | 2025 | 54.610% |
| fixation_type | cementless femoral component fixation | 2025 | 44.140% |
| geography | North America | 2025 | 42.410% |
| indication | primary osteoarthritis | 2025 | 61.140% |
| material_and_bearing_couple | cobalt-chromium alloy | 2025 | 41.240% |
| product_type | metal-on-metal implants | 2025 | 39.310% |
关键结论
- end_user 维度中，hospitals 在 2025 年的公开份额为 54.61%。
- fixation_type 维度中，cementless femoral component fixation 在 2025 年的公开份额为 44.14%。
- geography 维度中，North America 在 2025 年的公开份额为 42.41%。
- indication 维度中，primary osteoarthritis 在 2025 年的公开份额为 61.14%。
- material_and_bearing_couple 维度中，cobalt-chromium alloy 在 2025 年的公开份额为 41.24%。
- product_type 维度中，metal-on-metal implants 在 2025 年的公开份额为 39.31%。
主要参与者
- Smith & Nephew
- Zimmer Biomet
- Stryker
- Corin Group
- Johnson & Johnson
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Bone-Conserving Arthroplasty for Younger, Active Patients | +1.800% | Global, led by North America, the UK, Germany, and Australia | Long term (≥ 4 years) |
| Expanded Diagnosis and Surgical Treatment of Hip Osteoarthritis | +1.500% | Global, highest impact in high-income North America and Western Europe | Medium term (2-4 years) |
| Robotic and Computer-Assisted Component Positioning | +0.900% | North America, Western Europe, Japan, South Korea | Medium term (2-4 years) |
| Orthopedic Capacity and Private Healthcare Growth in Emerging Economies | +1.000% | APAC core, India, China, South Korea, with spillover to MEA | Long term (≥ 4 years) |
| Ceramic and Low-Wear Bearings Expanding Patient Eligibility | +0.800% | UK, EU, Australia, and Canada, following July 2026 approval | Short term (≤ 2 years) |
| Surgeon-Led Training Networks Building Procedure-Specific Demand | +0.500% | North America, UK, Western Europe, Australia | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Metal-Ion Release, Pseudotumor, and Adverse Local Tissue Reaction Concerns | -1.500% | Global, most acute in US, UK, and EU | Long term (≥ 4 years) |
| Regulatory Scrutiny, Litigation, and Product Recall Risk | -1.000% | US, EU, Australia | Medium term (2-4 years) |
| Limited Surgeon Training Capacity and Procedure Learning Curve | -0.700% | Global, most pronounced in Asia-Pacific and Latin America | Long term (≥ 4 years) |
| Reimbursement and Hospital Procurement Friction for Specialized Systems | -0.600% | Western Europe, US public payers, and secondary APAC public hospital systems | Medium term (2-4 years) |
报告关注的关键问题
What is driving demand for hip resurfacing implants?
Demand is supported by the need to preserve bone in younger active patients who may face future revision surgery. Rising hip osteoarthritis burden creates a larger population requiring orthopedic assessment.
What is the forecast growth rate for hip resurfacing implants?
The hip resurfacing implants market is projected to grow at a 6.72% CAGR from 2026 to 2031.
Which hip resurfacing product type is growing fastest?
Ceramic-on-ceramic implants are projected to grow at a 7.85% CAGR through 2031. Their growth reflects a need for alternatives to metal-on-metal devices and a broader set of potential patient anatomies.
Which care setting is expanding most quickly for hip resurfacing?
Ambulatory surgical centers are forecast to grow at an 8.25% CAGR through 2031. Their expansion follows wider interest in outpatient orthopedic pathways, although hospitals remain necessary for complex cases that require imaging, experienced teams, and robotic equipment.
Which region will grow fastest through 2031?
Asia-Pacific is projected to expand at an 8.05% CAGR. Healthcare investment, private surgical capacity, and demographic demand support this outlook.
What is the main barrier to treatment access?
Annual list prices ranging from USD 244,000 to USD 464,000 and evidence-based reimbursement requirements remain major barriers.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence